Sign in or create an account to add this stock to your watchlist.
About Adaptimmune Therapeutics (NASDAQ:ADAP)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADAP
CUSIPN/A
Phone44-12-3543-0000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.77
Quick Ratio3.77
Price-To-Earnings
Trailing P/E Ratio-16.64
Forward P/E Ratio-15.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$37.83 million
Price / Sales33.12
Cash FlowN/A
Price / CashN/A
Book Value$2.03 per share
Price / Book6.56
Profitability
EPS (Most Recent Fiscal Year)($0.80)
Net Income$-70,130,000.00
Net Margins-160.83%
Return on Equity-32.57%
Return on Assets-24.93%
Miscellaneous
Employees371
Outstanding Shares94,140,000
Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions
What is Adaptimmune Therapeutics' stock symbol?
Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."
How were Adaptimmune Therapeutics' earnings last quarter?
Adaptimmune Therapeutics (NASDAQ:ADAP) announced its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.04. The biotechnology company had revenue of $4.27 million for the quarter, compared to analysts' expectations of $9.38 million. Adaptimmune Therapeutics had a negative return on equity of 32.57% and a negative net margin of 160.83%. View Adaptimmune Therapeutics' Earnings History.
When is Adaptimmune Therapeutics' next earnings date?
What price target have analysts set for ADAP?
4 brokerages have issued twelve-month price targets for Adaptimmune Therapeutics' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Adaptimmune Therapeutics' share price to reach $17.6667 in the next twelve months. View Analyst Ratings for Adaptimmune Therapeutics.
What are Wall Street analysts saying about Adaptimmune Therapeutics stock?
Here are some recent quotes from research analysts about Adaptimmune Therapeutics stock:
- 1. Cowen Inc analysts commented, "We continue to expect positive data for the five-dose combination Phase 2 cohorts in 3Q18, and anticipate sustained serum uric acid suppression without ADAs. Selecta will present data for patients receiving 0.10 – 0.15 mg/kg SVP rapamycin combined with 0.2 mg/kg pegsiticase. The company plans to present multiple cohorts with up to n=20 patients per group. We expect data in 3Q18 to include a number of patients who have completed the full 5/6 dose combination regimen." (5/9/2018)
- 2. Raymond James analysts commented, "Benjamin observed: Benjamin observed: We are maintaining our Outperform rating and increasing our price target to $20 (previously was $11) for ADAP given our increasing confidence in the company’s TCR franchise. Yesterday, the company reported 4Q17 financial results and provided an update on its TCR programs. Key takeaways include: 1) three partial responses (PRs) achieved by the NY- ESO TCR among four patients with myxoid/ round cell liposarcoma (MRCLS); 2) a slew of additional data readouts expected throughout 2018, including the first efficacy results from the MAGE-A10 and MAGE-A4 studies anticipated in 2H18; and 3) a cash runway through early 2020. With growing evidence from the NY-ESO TCR, multiple clinical data readouts expected from the wholly owned assets in 2018, a marquee partner like GlaxoSmithKline to move the NY-ESO program into pivotal studies, and a strong cash position of $188 million (pro forma), we continue to recommend shares of Adaptimmune to long-term, risk tolerant investors."
" (4/22/2018)
- 3. According to Zacks Investment Research, "Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. " (3/19/2018)
Who are some of Adaptimmune Therapeutics' key competitors?
Some companies that are related to Adaptimmune Therapeutics include CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Repligen (RGEN), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA).
Who are Adaptimmune Therapeutics' key executives?
Adaptimmune Therapeutics' management team includes the folowing people:
- Mr. James Julian Noble, Chief Exec. Officer and Director (Age 59)
- Mr. Adrian Rawcliffe, Chief Financial Officer (Age 46)
- Dr. Rafael Amado M.D., Chief Medical Officer (Age 54)
- Dr. Bent Jakobsen Ph.D., Scientific Co-Founder
- Dr. Helen Katrina Tayton-Martin, Co-Founder and Chief Bus. Officer (Age 51)
When did Adaptimmune Therapeutics IPO?
(ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
Has Adaptimmune Therapeutics been receiving favorable news coverage?
Media stories about ADAP stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Adaptimmune Therapeutics earned a news sentiment score of 0.21 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.65 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Adaptimmune Therapeutics' major shareholders?
Adaptimmune Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (14.23%), Baillie Gifford & Co. (2.74%), Millennium Management LLC (1.58%), BlackRock Inc. (0.86%), Foresite Capital Management II LLC (0.43%) and JPMorgan Chase & Co. (0.20%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, David M Mott, Enterprise Associates 14 New, Orbimed Advisors Llc, Peter A Thompson and Ravi Viswanathan. View Institutional Ownership Trends for Adaptimmune Therapeutics.
Which major investors are selling Adaptimmune Therapeutics stock?
ADAP stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Orbimed Advisors Llc and Peter A Thompson. View Insider Buying and Selling for Adaptimmune Therapeutics.
Which major investors are buying Adaptimmune Therapeutics stock?
ADAP stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Millennium Management LLC, Baillie Gifford & Co., Foresite Capital Management II LLC, JPMorgan Chase & Co., A.R.T. Advisors LLC, GSA Capital Partners LLP and DekaBank Deutsche Girozentrale. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include David M Mott, Enterprise Associates 14 New, Orbimed Advisors Llc and Ravi Viswanathan. View Insider Buying and Selling for Adaptimmune Therapeutics.
How do I buy shares of Adaptimmune Therapeutics?
Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adaptimmune Therapeutics' stock price today?
One share of ADAP stock can currently be purchased for approximately $13.31.
How big of a company is Adaptimmune Therapeutics?
Adaptimmune Therapeutics has a market capitalization of $1.24 billion and generates $37.83 million in revenue each year. The biotechnology company earns $-70,130,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Adaptimmune Therapeutics employs 371 workers across the globe.
How can I contact Adaptimmune Therapeutics?
Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]
MarketBeat Community Rating for Adaptimmune Therapeutics (ADAP)
MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics and other stocks. Vote "Outperform" if you believe ADAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Adaptimmune Therapeutics in the last 12 months. Their average twelve-month price target is $17.6667, suggesting that the stock has a possible upside of 32.73%. The high price target for ADAP is $20.00 and the low price target for ADAP is $15.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.6667 | $15.00 | $12.50 | $12.50 |
| Price Target Upside: | 32.73% upside | 20.58% upside | 54.32% upside | 54.32% upside |
Adaptimmune Therapeutics (NASDAQ:ADAP) Consensus Price Target History
Adaptimmune Therapeutics (NASDAQ:ADAP) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Adaptimmune Therapeutics (NASDAQ:ADAP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Adaptimmune Therapeutics (NASDAQ ADAP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 26.47%
Institutional Ownership Percentage: 59.95%
Adaptimmune Therapeutics (NASDAQ ADAP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/14/2018 | Peter A Thompson | Director | Sell | 10,300 | $13.50 | $139,050.00 | |  |
| 3/29/2018 | Orbimed Advisors Llc | Director | Sell | 1,048,067 | $11.50 | $12,052,770.50 | | |
| 3/27/2018 | Enterprise Associates 14 New | Major Shareholder | Buy | 6,571,164 | $1.92 | $12,616,634.88 | | |
| 3/26/2018 | David M Mott | Director | Buy | 571,164 | $1.90 | $1,085,211.60 | | |
| 3/23/2018 | Enterprise Associates 14 New | Major Shareholder | Buy | 1,268,508 | $1.91 | $2,422,850.28 | | |
| 3/22/2018 | David M Mott | Director | Buy | 869,574 | $1.90 | $1,652,190.60 | | |
| 3/21/2018 | Ravi Viswanathan | Major Shareholder | Buy | 104,844 | $1.81 | $189,767.64 | | |
| 3/20/2018 | Adrian Rawcliffe | CFO | Sell | 600,000 | $1.71 | $1,026,000.00 | | |
| 3/27/2017 | Enterprise Associates 14 New | Major Shareholder | Buy | 12,870,000 | $0.70 | $9,009,000.00 | | |
| 3/27/2017 | Orbimed Advisors Llc | Director | Buy | 1,190,476 | $4.20 | $4,999,999.20 | | |
| 5/24/2016 | Orbimed Advisors Llc | Director | Buy | 1,712,400 | $10.42 | $17,843,208.00 | | |
| 5/19/2016 | Charles Elliott Sigal | Director | Buy | 15,000 | $1.56 | $23,400.00 | 52,938 | |
| 5/18/2016 | Charles Elliott Sigal | Director | Buy | 45,000 | $1.53 | $68,850.00 | 52,938 | |
(Data available from 1/1/2013 forward)
Adaptimmune Therapeutics (NASDAQ ADAP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Adaptimmune Therapeutics (ADAP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 20 at 1:40 PM |
 | Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American ...
globenewswire.com - May 18 at 9:09 AM |
 | Don't Buy L Brands - Cramer's Lightning Round (5/15/18)
seekingalpha.com - May 18 at 9:09 AM |
 | Adaptimmune Therapeutics (ADAP) Data with NY-ESO and MAGE-A10 Study Update to be Presented at ASCO
www.streetinsider.com - May 17 at 5:49 PM |
| Adaptimmune Therapeutics (ADAP) Director Sells $139,050.00 in Stock
www.americanbankingnews.com - May 16 at 8:19 PM |
| Adaptimmune Therapeutics (ADAP) Expected to Post Quarterly Sales of $7.76 Million
www.americanbankingnews.com - May 16 at 4:26 AM |
| Adaptimmune Therapeutics (ADAP) Lowered to Hold at BidaskClub
www.americanbankingnews.com - May 15 at 1:21 PM |
 | Wired News – VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine
finance.yahoo.com - May 14 at 9:00 AM |
| Adaptimmune Therapeutics (ADAP) Expected to Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - May 14 at 3:24 AM |
| SunTrust Banks Analysts Lower Earnings Estimates for Adaptimmune Therapeutics (ADAP)
www.americanbankingnews.com - May 14 at 2:50 AM |
| Adaptimmune Therapeutics Expected to Post FY2018 Earnings of ($1.08) Per Share (ADAP)
www.americanbankingnews.com - May 11 at 11:03 AM |
| Adaptimmune Therapeutics Expected to Post Q3 2018 Earnings of $0.29 Per Share (ADAP)
www.americanbankingnews.com - May 11 at 10:00 AM |
| Adaptimmune Therapeutics (ADAP) Price Target Increased to $18.00 by Analysts at SunTrust Banks
www.americanbankingnews.com - May 10 at 7:05 PM |
| Edited Transcript of ADAP earnings conference call or presentation 9-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 8:49 AM |
| Cowen Reiterates "Buy" Rating for Adaptimmune Therapeutics (ADAP)
www.americanbankingnews.com - May 9 at 9:42 PM |
| Adaptimmune Therapeutics (ADAP) Given a $20.00 Price Target by Raymond James Analysts
www.americanbankingnews.com - May 9 at 6:10 PM |
| Adaptimmune Therapeutics' (ADAP) CEO James Noble on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:14 PM |
| Adaptimmune Therapeutics (ADAP) Posts Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - May 9 at 2:19 PM |
| Financial Review: Adaptimmune Therapeutics (ADAP) vs. Solid Biosciences (SLDB)
www.americanbankingnews.com - May 7 at 11:08 PM |
| Adaptimmune Therapeutics (ADAP) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:46 AM |
| Adaptimmune Therapeutics (ADAP) Expected to Announce Quarterly Sales of $7.59 Million
www.americanbankingnews.com - April 28 at 2:46 AM |
| Brokerages Anticipate Adaptimmune Therapeutics (ADAP) to Post -$0.24 EPS
www.americanbankingnews.com - April 26 at 3:10 PM |
| Adaptimmune Therapeutics (ADAP) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 25 at 1:36 PM |
| Adaptimmune Therapeutics (ADAP) Given Buy Rating at Raymond James
www.americanbankingnews.com - April 22 at 7:44 AM |
 | Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia ...
www.prnewswire.com - April 19 at 5:19 PM |
| Adaptimmune Therapeutics (ADAP) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - April 18 at 12:50 PM |
| Adaptimmune Therapeutics (ADAP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 17 at 10:29 AM |
| Adaptimmune Therapeutics (ADAP) Presents MAGE-A4 and MAGE-A10 pre-clinical data at AACR
www.streetinsider.com - April 16 at 5:04 PM |
| Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 16 at 5:04 PM |
| Head-To-Head Survey: Adaptimmune Therapeutics (ADAP) vs. Vaxart (VXRT)
www.americanbankingnews.com - April 12 at 11:19 PM |
| Adaptimmune Therapeutics (ADAP) Appoints John Furey to Board, Replacing Peter Thompson, MD
www.streetinsider.com - April 12 at 9:15 AM |
 | 28 Stocks Moving In Thursday's Pre-Market Session
www.benzinga.com - April 12 at 9:15 AM |
| Zacks: Analysts Anticipate Adaptimmune Therapeutics (ADAP) Will Post Quarterly Sales of $7.59 Million
www.americanbankingnews.com - April 11 at 2:23 AM |
 | Report: Exploring Fundamental Drivers Behind Brookfield Property Partners, Grupo Financiero Galicia
www.nasdaq.com - April 9 at 8:50 AM |
| Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 6 at 8:52 AM |
| Adaptimmune Therapeutics (ADAP) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - April 3 at 8:14 PM |
| Adaptimmune Therapeutics (ADAP) Upgraded by TheStreet to C
www.americanbankingnews.com - April 1 at 8:42 PM |
| Adaptimmune Therapeutics PLC - (ADAP) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 31 at 1:36 PM |
| Adaptimmune Therapeutics PLC - (ADAP) Director Orbimed Advisors Llc Sells 1,048,067 Shares
www.americanbankingnews.com - March 29 at 10:10 PM |
| Adaptimmune Therapeutics PLC - (ADAP) Major Shareholder Enterprise Associates 14 New Purchases 6,571,164 Shares
www.americanbankingnews.com - March 28 at 10:31 PM |
| Adaptimmune Therapeutics PLC - (ADAP) Director Acquires $1,085,211.60 in Stock
www.americanbankingnews.com - March 28 at 10:31 PM |
| Adaptimmune Stock: How Long Will Rally Continue?
finance.yahoo.com - March 26 at 4:59 PM |
| $7.59 Million in Sales Expected for Adaptimmune Therapeutics PLC - (ADAP) This Quarter
www.americanbankingnews.com - March 25 at 2:52 AM |
| Adaptimmune Therapeutics (ADAP) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - March 24 at 4:30 PM |
| Form 4 New Enterprise Associate For: Mar 21 Filed by: Adaptimmune Therapeutics PLC - StreetInsider.com
www.streetinsider.com - March 24 at 9:09 AM |
| Adaptimmune Therapeutics (ADAP) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 23 at 8:28 PM |
| Adaptimmune Therapeutics PLC - (ADAP) Major Shareholder Acquires $189,767.64 in Stock
www.americanbankingnews.com - March 23 at 7:32 PM |
| Adaptimmune Therapeutics PLC - (ADAP) Major Shareholder Acquires $2,422,850.28 in Stock
www.americanbankingnews.com - March 23 at 7:16 PM |
| David M. Mott Acquires 869,574 Shares of Adaptimmune Therapeutics PLC - (ADAP) Stock
www.americanbankingnews.com - March 23 at 7:15 PM |
| Investors Buy High Volume of Call Options on Adaptimmune Therapeutics (ADAP)
www.americanbankingnews.com - March 23 at 7:30 AM |
Adaptimmune Therapeutics (NASDAQ:ADAP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Adaptimmune Therapeutics (NASDAQ:ADAP) Income Statement, Balance Sheet and Cash Flow Statement
Adaptimmune Therapeutics (NASDAQ ADAP) Stock Chart for Friday, May, 25, 2018
Loading chart…
